Monographie - Melphalan

Seneste opdatering :
19/11/2024

Melphalan

Kemisk struktur

Handelsnavn

Handel navne er vejledende og hjælpestoffer sammensætning kan være forskellig afhængigt af landet og laboratorier

Alkeran	Australien, Belgien, Brasilien, Canada, Chile, Colombia, Forenede Arabiske Emirater, Frankrig, Grækenland, Irland, Italien, Luxemborg, Malaysia, New Zealand, Schweiz, Storbritanien, Sverige, Tyskland, USA, Østrig
Egymelan	Marokko
Eriolan	Argentina, Ecuador
Melfalan	Argentina, Chile, Ecuador, Spanien, Tyskland
Melfoma	Argentina, Marokko

Bibliografi : Melphalan

	Type	offentliggørelse
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
160	Journal	Pinguet F, Martel P, Rouanet P, Fabbro M, Astre C. Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. Am J Hosp Pharm 1994 ; 51: 2701-2704.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
854	Journal	Chang SY, Evans TL, Alberts DS. The stability of melphalan in the presence of chloride ion. J Pharm Pharmacol 1979 ; 31: 853-854.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1501	Journal	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Laboratorium	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
2247	Journal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3516	Poster	Vigneron J, Zenier H, May I, Nicolas A. Stabilité du melphalan à 2 mg/ml dans le chlorure de sodium 0,9% dans des conditions pratiques d'utilisation. SFPO Congress, Mandelieu, France. 2013
3584	Laboratorium	Melphalan (Alkéran®) - Résumé des caractéristiques du produit Aspen Pharma 2013
3786	Journal	Buitrago E, Lagomarsino E; Mato G; Schaiquevich P. Stability of Melphalan Solution for Intravitreal Injection for Retinoblastoma JAMA Ophtalmology 2014 ; 132, 11: 1372-1373.
3949	Poster	Brönnimann C, Berger-Gryllaki M, Podilsky G, Sadeghipour F. Optimisation du processus de préparation des solutions de melphalan destinées à l’administration intra-vitréenne dans le traitement du rétinoblastome et étude de leur stabilité JFSPH Congress, Bern, Switzerland. 2016
3977	Journal	Desmaris R.P, Mercier L, Paci A. Stability of Melphalan in 0,9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection. Drugs R D 2015 ;15:253-259.
4189	Journal	Kawedia J, Ramchandran S, Liu X, Gulbis A, Titus M, Bashir Q, Qazilbash M, Champlin R, Ciur S, Stability of Captisol-enabled versus propylene glycol–based melphalan at room temperature and after refrigeration. Am J Health-Syst Pharm 2022 ;79,12: 1011-1018
4376	Journal	Shi Z, Abruzzo T, Wanasathop A, Li S K. Compatibility of Melphalan in Iodinated Contrast Media. Int J Pharm Compound 2020 ;24,1:83-85
4701	Journal	Singh R, Chen J, Miller T, Bergren M, Mallik R. Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection. Pharm Dev Technol 2018 ; 23, 10: 1024-1029.

Mentions Légales